ATE419854T1 - Verfahren zur herstellung einer latanoprost- augenlösung und so hergestellte lösung - Google Patents

Verfahren zur herstellung einer latanoprost- augenlösung und so hergestellte lösung

Info

Publication number
ATE419854T1
ATE419854T1 AT04748557T AT04748557T ATE419854T1 AT E419854 T1 ATE419854 T1 AT E419854T1 AT 04748557 T AT04748557 T AT 04748557T AT 04748557 T AT04748557 T AT 04748557T AT E419854 T1 ATE419854 T1 AT E419854T1
Authority
AT
Austria
Prior art keywords
solution
preparing
produced
latanoprost eye
latanoprost
Prior art date
Application number
AT04748557T
Other languages
English (en)
Inventor
Bayardo Arturo Jimenez
Montano Jose Ruben Tornero
Sanchez Maria Isabel Lopez
Olmos Enrique Cruz
Original Assignee
Bayardo Arturo Jimenez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35450648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE419854(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayardo Arturo Jimenez filed Critical Bayardo Arturo Jimenez
Application granted granted Critical
Publication of ATE419854T1 publication Critical patent/ATE419854T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT04748557T 2004-05-26 2004-05-26 Verfahren zur herstellung einer latanoprost- augenlösung und so hergestellte lösung ATE419854T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2004/000034 WO2005115401A1 (es) 2004-05-26 2004-05-26 Un método para preparar una solución oftálmica de latanoprost y solución resultante

Publications (1)

Publication Number Publication Date
ATE419854T1 true ATE419854T1 (de) 2009-01-15

Family

ID=35450648

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04748557T ATE419854T1 (de) 2004-05-26 2004-05-26 Verfahren zur herstellung einer latanoprost- augenlösung und so hergestellte lösung

Country Status (12)

Country Link
US (4) US8293789B2 (de)
EP (1) EP1759702B1 (de)
AR (1) AR049113A1 (de)
AT (1) ATE419854T1 (de)
BR (1) BRPI0418866A (de)
DE (1) DE602004018990D1 (de)
DK (1) DK1759702T3 (de)
ES (1) ES2320770T3 (de)
PL (1) PL1759702T3 (de)
PT (1) PT1759702E (de)
SI (1) SI1759702T1 (de)
WO (1) WO2005115401A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609634B2 (en) * 2007-05-16 2013-12-17 Mcneil-Ppc, Inc. Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods
US9579341B2 (en) 2007-05-16 2017-02-28 Johnson & Johnson Consumer Inc. Preserved compositions containing hyaluronic acid or a pharmaceutically-acceptable salt thereof and related methods
US20100130444A1 (en) * 2007-07-11 2010-05-27 El Mustapha Belgsir Complexes of prostaglandin derivatives and monosubstituted, charged beta-cyclodextrins
ES2667945T3 (es) 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
US8455547B2 (en) 2008-02-05 2013-06-04 Allergan, Inc. Substituted cyclopentanes having prostaglandin activity
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
US9481856B2 (en) * 2008-06-09 2016-11-01 Bausch & Lomb Incorporated Pharmaceutical formulations comprising stabilized polysaccharides and source of hydrogen peroxide
US10463677B2 (en) * 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
EP2393490A1 (de) * 2009-02-04 2011-12-14 INSERM - Institut National de la Santé et de la Recherche Médicale Taurin- bzw. taurinartige substanzen zur vorbeugung und behandlung einer krankheit im zusammenhang mit retinaler ganglienzellendegeneration
DE102009021372A1 (de) * 2009-05-14 2010-11-18 Ursapharm Arzneimittel Gmbh Phosphatfreie pharmazeutische Zusammensetzung zur Glaukombehandlung
EP2440185B1 (de) * 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topische arzneimittelabgabesysteme zur ophthalmischen verwendung
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
DE102011108948A1 (de) * 2011-07-29 2013-01-31 Achim Göpferich Wässrige, kolloidale Lösungen von lipophilen Substanzen,insbesondere Arzneistofflösungen
EP2567689A1 (de) * 2011-09-12 2013-03-13 Visiotact Pharma Ophthalmische Zusammensetzungen enhaltend Prostaglandin-F2-alpha-Derivate und Hyaluronsäure
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
ES2669446B1 (es) * 2016-11-24 2019-03-13 Saiz Manuel Munoz Producto oftálmico
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
GR1009419B (el) * 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου
JP2022519580A (ja) * 2019-02-06 2022-03-24 ティアークリアー コープ． 複合体化剤を含む眼科用製剤から防腐剤を除去するためのシステムおよび方法
EP4331683A3 (de) 2019-08-07 2024-08-07 Aneira Pharma, Inc. Verfahren und zusammensetzungen zur behandlung von haarausfall
US12539302B2 (en) 2019-08-07 2026-02-03 Aneira Pharma, Inc. Methods and compositions for the treatment of hair loss
PL4167965T3 (pl) * 2020-06-21 2025-03-24 i.com medical GmbH Zastosowanie kwasu hialuronowego o wysokiej masie cząsteczkowej jako nośnika do transportu do oczu

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU665287B2 (en) * 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
ATE289817T1 (de) * 1998-12-25 2005-03-15 Sucampo Ag Arzneimittelzusammenstellung zur behandlung des erhöhten augeninnendrucks oder des glaukom
AU2001233286B2 (en) * 2000-02-01 2006-04-06 Cayman Chemical Company, Incorporated Internal 1,15-lactones of fluprostenol and related prostaglandin F2alpha analogs and their use in the treatment of glaucoma and intraocular hypertension
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
PE20020578A1 (es) * 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
US20030018079A1 (en) 2000-11-13 2003-01-23 Richardson Helene Treatment

Also Published As

Publication number Publication date
WO2005115401A1 (es) 2005-12-08
AR049113A1 (es) 2006-06-28
SI1759702T1 (sl) 2009-06-30
PL1759702T3 (pl) 2009-06-30
ES2320770T3 (es) 2009-05-28
US20080021101A1 (en) 2008-01-24
US20110098355A1 (en) 2011-04-28
US8293789B2 (en) 2012-10-23
US20110105605A1 (en) 2011-05-05
DE602004018990D1 (de) 2009-02-26
BRPI0418866A (pt) 2007-11-20
PT1759702E (pt) 2009-04-13
DK1759702T3 (da) 2009-04-20
EP1759702B1 (de) 2009-01-07
EP1759702A1 (de) 2007-03-07
US20110098354A1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
ATE419854T1 (de) Verfahren zur herstellung einer latanoprost- augenlösung und so hergestellte lösung
ATE408609T1 (de) Verfahren zur herstellung von n-phenylpyrazol-1- carboxamiden
DE602005012823D1 (de) Schmirgelleinen und verfahren zur herstellung einer nanofaserstruktur
ATE516816T1 (de) Verfahren zur herstellung von impfstoffen
DE602005027235D1 (de) Verfahren zur herstellung einer fotomaske
DE602005019848D1 (de) Verfahren zur herstellung von tad- getrocknetem ti
DE502005002059D1 (de) Verfahren zur herstellung von polyetheralkoholen
DE502005010038D1 (de) Verfahren zur herstellung von 3-pentennitril
EP1792899A4 (de) Verfahren zur herstellung von optisch aktiven aminderivaten
DE602005020148D1 (de) Verfahren zur herstellung einer mems-vorrichtung
DE602004027229D1 (de) Verfahren zur herstellung von photonischer kristallfaser
DE602004021697D1 (de) Verfahren zur herstellung einer wabenstruktur
DE602005003082D1 (de) Verfahren zur Herstellung einer Vorrichtung
DE502005005281D1 (de) Verfahren zur herstellung einer nockenwelle
DE602005017099D1 (de) Verfahren zur Herstellung von amorphem Cefuroximaxetil
DE502005006608D1 (de) Verfahren zur herstellung einer steckverbindung
DE602005014893D1 (de) Verfahren zur herstellung eines pvp-fulleren-komplexes und wässrige lösung davon
ATE460414T1 (de) Verfahren zur herstellung von tiotropiumsalzen
ATE406372T1 (de) Verfahren zur herstellung von 3-o-geschützten morphinonen und 3-o-geschützten morphinondienolcarboxylaten
ATE542533T1 (de) Verfahren zur herstellung von isothiazol- derivaten
DE602005025849D1 (de) Verfahren und Vorrichtung zur Herstellung einer Durchgangsbohrung
DE502004003171D1 (de) Verfahren zur herstellung von bauteilen einer gastubine
DE502005001066D1 (de) Nockenwelle und verfahren zur herstellung einer nockenwelle
ATE458741T1 (de) Verfahren zur herstellung von phthalocyaninen
ATA1142001A (de) Verfahren zur herstellung eines turmartigen bauwerks

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1759702

Country of ref document: EP